161 related articles for article (PubMed ID: 35775313)
101. Quality-adjusted life years for HER2-positive, early-stage breast cancer using trastuzumab-containing regimens in the context of cost-effectiveness studies: a systematic review.
Khoirunnisa SM; Suryanegara FDA; Setiawan D; Postma MJ
Expert Rev Pharmacoecon Outcomes Res; 2024 Jun; 24(5):613-629. PubMed ID: 38738869
[TBL] [Abstract][Full Text] [Related]
102. Cost-Effectiveness Analysis of Adjuvant Olaparib Versus Watch and Wait in the Treatment of Germline BRCA1/2-Mutated, High-Risk, HER2-Negative Early Breast Cancer in Sweden.
Polyzoi M; Ekman M; Reithmeier A; Jacob J; Karlsson E; Bertranou E; Linderholm B; Hettle R
Pharmacoecon Open; 2024 Mar; 8(2):277-289. PubMed ID: 38093030
[TBL] [Abstract][Full Text] [Related]
103. Cost-effectiveness analysis of prophylactic laser peripheral iridotomy for primary angle-closure suspect in Japan.
Fujita A; Konishi T; Sakata R; Hashimoto Y; Yasunaga H; Aihara M
Eye (Lond); 2024 Apr; 38(5):930-936. PubMed ID: 37898717
[TBL] [Abstract][Full Text] [Related]
104. Cost-effectiveness of trastuzumab deruxtecan in previously treated human epidermal growth factor receptor 2-low metastatic breast cancer.
Yang J; Han J; Zeng N; Yan X
Ther Adv Med Oncol; 2023; 15():17588359231169983. PubMed ID: 37228255
[TBL] [Abstract][Full Text] [Related]
105. Real-Life Use and Effectiveness of Adjuvant Trastuzumab in Early Breast Cancer Patients: A Study of the Southeast Netherlands Breast Cancer Consortium.
Seferina SC; Lobbezoo DJ; de Boer M; Dercksen MW; van den Berkmortel F; van Kampen RJ; van de Wouw AJ; de Vries B; Joore MA; Peer PG; Voogd AC; Tjan-Heijnen VC
Oncologist; 2015 Aug; 20(8):856-63. PubMed ID: 26099745
[TBL] [Abstract][Full Text] [Related]
106. Lapatinib in patients with metastatic breast cancer following initial treatment with trastuzumab: an economic analysis from the Brazilian public health care perspective.
Machado M; Einarson TR
Breast Cancer (Dove Med Press); 2012; 4():173-82. PubMed ID: 24367204
[TBL] [Abstract][Full Text] [Related]
107. Combination chemotherapy with trastuzumab in early-stage breast cancer: a meta-analysis and Bayesian decision analysis of different treatment regimens.
Liu Q
Eur Rev Med Pharmacol Sci; 2024 Jan; 28(1):231-241. PubMed ID: 38235874
[TBL] [Abstract][Full Text] [Related]
108. Cost-minimisation analysis of intravenous versus subcutaneous trastuzumab regimen for breast cancer management in Hong Kong.
Lee VWY; Cheng FWT
Hong Kong Med J; 2023 Feb; 29(1):16-21. PubMed ID: 36731884
[TBL] [Abstract][Full Text] [Related]
109. Estimating the Product Lifecycle Value of Trastuzumab Based on Registry Data in Sweden.
Justo N; Wilking N; Jönsson L
Clin Drug Investig; 2023 Jul; 43(7):529-540. PubMed ID: 37422544
[TBL] [Abstract][Full Text] [Related]
110. Cost-effectiveness analysis of abemaciclib with endocrine therapy (ET) versus ET alone for HR+, HER2-, node-positive, high-risk early breast cancer in Italy.
Davie A; Traoré S; Giovannitti M; Pompilio G; Lambton M; Cakar E; Chatterjee A
Glob Reg Health Technol Assess; 2023; 10():62-69. PubMed ID: 37811343
[TBL] [Abstract][Full Text] [Related]
111. Cost-effectiveness analysis of adjuvant treatment for resected pancreatic cancer in China based on the ESPAC-4 trial.
Huang J; Liao W; Zhou J; Zhang P; Wen F; Wang X; Zhang M; Zhou K; Wu Q; Li Q
Cancer Manag Res; 2018; 10():4065-4072. PubMed ID: 30323662
[TBL] [Abstract][Full Text] [Related]
112. Economic evaluation of third-line neratinib plus capecitabine versus lapatinib plus capecitabine with HER2+ metastatic breast cancer.
Ren L; Ren N; Zheng Y; Yang Y; Xu Q
Front Oncol; 2023; 13():1221969. PubMed ID: 37621688
[TBL] [Abstract][Full Text] [Related]
113. Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer.
Reed SD; Dinan MA; Schulman KA; Lyman GH
Genet Med; 2013 Mar; 15(3):203-11. PubMed ID: 22975761
[TBL] [Abstract][Full Text] [Related]
114. The Cost-Effectiveness of Pertuzumab for the Treatment of Metastatic HER2+ Breast Cancer in Czechia: A Semi-Markov Model Using Cost States.
Šlegerová L; Kopečková K
Value Health Reg Issues; 2023 Nov; 38():118-125. PubMed ID: 37865065
[TBL] [Abstract][Full Text] [Related]
115. Evaluating the cost utility of estradiol plus dydrogesterone for the treatment of menopausal women in China.
Tamlyn Anne R; Downes M; Simoncini T; Yu Q; Ren M; Wang Y; Graziano CM; Kim K
J Med Econ; 2024; 27(1):16-26. PubMed ID: 38037348
[TBL] [Abstract][Full Text] [Related]
116. Cost-Effectiveness Analysis of Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib for Inoperable or Recurrent Breast Cancer.
Shida T; Kaneko M; Ogura J; Sawada H; Hatakeyama S; Arakawa I; Yamaguchi H; Inoue T
Gan To Kagaku Ryoho; 2023 Aug; 50(8):895-900. PubMed ID: 37608416
[TBL] [Abstract][Full Text] [Related]
117. Three Versus Six Months of Adjuvant Doublet Chemotherapy for Patients With Colorectal Cancer: A Multi-Country Cost-Effectiveness and Budget Impact Analysis.
Hanna CR; Robles-Zurita JA; Briggs A; Harkin A; Kelly C; McQueen J; Allan K; Pearson S; Hollander H; Glimelius B; Salazar R; Segelov E; Saunders M; Iveson T; Jones RJ; Boyd KA
Clin Colorectal Cancer; 2021 Sep; 20(3):236-244. PubMed ID: 33992542
[TBL] [Abstract][Full Text] [Related]
118. Compliance to genomic test recommendations to guide adjuvant chemotherapy decision-making in the case of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer, in real-life settings.
Hequet D; Hajjaji N; Charafe-Jauffret E; Boucrauta A; Dalenc F; Nicolai V; Lopez J; Tredan O; Deluche E; Fermeaux V; Tixier L; Cayre A; Menet E; Lerebours F; Rouzier R
Cancer Med; 2023 Aug; 12(16):16889-16895. PubMed ID: 37409516
[TBL] [Abstract][Full Text] [Related]
119. Effectiveness of adjuvant trastuzumab in women with HER-2+ breast cancer in the SUS.
Batista JDL; Alves RJV; Cardoso TB; Moreno M; Tiscoski KA; Polanczyk CA
Cien Saude Colet; 2023 Jun; 28(6):1819-1830. PubMed ID: 37255158
[TBL] [Abstract][Full Text] [Related]
120.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
